SCHEMBL2866719

SCHEMBL2866719

COc1ccc(Cl)c(-n2nc3c(c2N)c(=O)[nH]c2cc(O)ccc23)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 5/20 0.43
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
LMNA P02545 1/20 0.38
ROCK2 O75116 1/20 0.36
TYMS P04818 1/20 0.35
FGFR1 P11362 1/20 0.35
SRC P12931 1/20 0.35
FGFR2 P21802 1/20 0.35
FGFR4 P22455 1/20 0.35
FGFR3 P22607 1/20 0.35
KDR P35968 1/20 0.35
KDM4E B2RXH2 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
USP2 O75604 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CHEK1 O14757 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2864647 0.90 PDE2A (0.44) PDE2AALDH1A1HPGDLMNATYMS
SCHEMBL2863002 0.89 KDM4E (0.39) PDE2AALDH1A1HPGDROCK2TYMS
SCHEMBL2870546 0.87 PDE2A (0.47) PDE2AALDH1A1HPGDKDM4ENPSR1
SCHEMBL2862251 0.87 PDE2A (0.42) PDE2ATYMSKDM4E
SCHEMBL2861961 0.85 CTSV (0.42) PDE2AALDH1A1HPGDLMNAKDM4E
SCHEMBL2862983 0.85 GAA (0.46) ALDH1A1LMNAKDM4EGAAMAPT
SCHEMBL2862177 0.83 ADORA3 (0.44) KDRMEN1KMT2A
SCHEMBL2860183 0.82 FGFR1 (0.46) PDE2AFGFR1SRCFGFR2FGFR4
SCHEMBL2868587 0.80 KDM4E (0.38) ALDH1A1HPGDLMNATYMSSRC
SCHEMBL2864971 0.79 CHEK1 (0.45) PDE2AALDH1A1HPGDROCK2TYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 PDE2A 2228/4885ALDH1A1 2391/4885HPGD 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.